BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 27222934)

  • 1. Anti-Angiotensin II Type 1 Receptor and Anti-Endothelial Cell Antibodies: A Cross-Sectional Analysis of Pathological Findings in Allograft Biopsies.
    Philogene MC; Bagnasco S; Kraus ES; Montgomery RA; Dragun D; Leffell MS; Zachary AA; Jackson AM
    Transplantation; 2017 Mar; 101(3):608-615. PubMed ID: 27222934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pre-transplant Screening for Non-HLA Antibodies: Who should be Tested?
    Philogene MC; Zhou S; Lonze BE; Bagnasco S; Alasfar S; Montgomery RA; Kraus E; Jackson AM; Leffell MS; Zachary AA
    Hum Immunol; 2018 Apr; 79(4):195-202. PubMed ID: 29428484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histopathologic changes in anti-angiotensin II type 1 receptor antibody-positive kidney transplant recipients with acute rejection and no donor specific HLA antibodies.
    Lim MA; Palmer M; Trofe-Clark J; Bloom RD; Jackson A; Philogene MC; Kamoun M
    Hum Immunol; 2017 Apr; 78(4):350-356. PubMed ID: 28284829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-HLA agonistic anti-angiotensin II type 1 receptor antibodies induce a distinctive phenotype of antibody-mediated rejection in kidney transplant recipients.
    Lefaucheur C; Viglietti D; Bouatou Y; Philippe A; Pievani D; Aubert O; Duong Van Huyen JP; Taupin JL; Glotz D; Legendre C; Loupy A; Halloran PF; Dragun D
    Kidney Int; 2019 Jul; 96(1):189-201. PubMed ID: 31005275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Impact of Pre-transplant Antibodies Against Angiotensin II Type I Receptor and Major Histocompatibility Complex Class I-Related Chain A in Kidney Transplant Patients.
    Min JW; Lee H; Choi BS; Park CW; Yang CW; Kim YS; Choi YJ; Oh EJ; Chung BH
    Ann Lab Med; 2018 Sep; 38(5):450-457. PubMed ID: 29797816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody-Mediated Rejection in Kidney Transplantation Without Evidence of Anti-HLA Antibodies?
    Irure J; López-Hoyos M; Rodrigo E; Gómez-Román J; Ruiz JC; Arias M; San Segundo D
    Transplant Proc; 2016 Nov; 48(9):2888-2890. PubMed ID: 27932099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A 3-Center Study Reveals New Insights Into the Impact of Non-HLA Antibodies on Lung Transplantation Outcome.
    Reinsmoen NL; Mirocha J; Ensor CR; Marrari M; Chaux G; Levine DJ; Zhang X; Zeevi A
    Transplantation; 2017 Jun; 101(6):1215-1221. PubMed ID: 27973391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of angiotensin II type 1 receptor antibodies with graft histology, function and survival in paediatric renal transplant recipients.
    Fichtner A; Süsal C; Schröder C; Höcker B; Rieger S; Waldherr R; Westhoff JH; Sander A; Dragun D; Tönshoff B
    Nephrol Dial Transplant; 2018 Jun; 33(6):1065-1072. PubMed ID: 29444269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The influence of non-HLA antibodies directed against angiotensin II type 1 receptor (AT1R) on early renal transplant outcomes.
    Banasik M; Boratyńska M; Kościelska-Kasprzak K; Kamińska D; Bartoszek D; Zabińska M; Myszka M; Zmonarski S; Protasiewicz M; Nowakowska B; Hałoń A; Chudoba P; Klinger M
    Transpl Int; 2014 Oct; 27(10):1029-38. PubMed ID: 24909812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pre-Transplant Angiotensin II Type 1 Receptor Antibodies and Anti-Endothelial Cell Antibodies Predict Graft Function and Allograft Rejection in a Low-Risk Kidney Transplantation Setting.
    Yu S; Huh HJ; Lee KW; Park JB; Kim SJ; Huh W; Jang HR; Kwon GY; Moon HH; Kang ES
    Ann Lab Med; 2020 Sep; 40(5):398-408. PubMed ID: 32311853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-HLA antibodies: angiotensin II type 1 receptor (anti-AT1R) and endothelin-1 type A receptor (anti-ETAR) are associated with renal allograft injury and graft loss.
    Banasik M; Boratyńska M; Kościelska-Kasprzak K; Kamińska D; Zmonarski S; Mazanowska O; Krajewska M; Bartoszek D; Zabińska M; Myszka M; Kamińska M; Hałoń A; Dawiskiba T; Szyber P; Sas A; Klinger M
    Transplant Proc; 2014 Oct; 46(8):2618-21. PubMed ID: 25380879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigation of Serum Angiotensin II Type 1 Receptor Antibodies at the Time of Renal Allograft Rejection.
    Lee H; Kim JI; Moon IS; Chung BH; Yang CW; Kim Y; Han K; Oh EJ
    Ann Lab Med; 2015 May; 35(3):314-20. PubMed ID: 25932439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ARHGDIB and AT1R autoantibodies are differentially related to the development and presence of chronic antibody-mediated rejection and fibrosis in kidney allografts.
    Betjes MGH; Sablik KA; Litjens NHR; Otten HG; de Weerd AE
    Hum Immunol; 2021 Feb; 82(2):89-96. PubMed ID: 33358038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of AT1R antibody (AT1R-Ab) among Malaysian multi-ethnic population.
    Jalalonmuhali M; Caroll R; Deayton S; Emery T; Humphreys I; Lim SJ; Lim SK; Coates T
    Hum Immunol; 2020 Dec; 81(12):679-684. PubMed ID: 32736900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pretransplant angiotensin II type 1-receptor antibodies are a risk factor for earlier detection of de novo HLA donor-specific antibodies.
    Cuevas E; Arreola-Guerra JM; Hernández-Méndez EA; Salcedo I; Castelán N; Uribe-Uribe NO; Vilatobá M; Contreras-Saldívar AG; Sánchez-Cedillo AI; Ramírez JB; de Rungs D; Granados J; Morales-Buenrostro LE; Alberú J
    Nephrol Dial Transplant; 2016 Oct; 31(10):1738-45. PubMed ID: 27220757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Higher risk of kidney graft failure in the presence of anti-angiotensin II type-1 receptor antibodies.
    Taniguchi M; Rebellato LM; Cai J; Hopfield J; Briley KP; Haisch CE; Catrou PG; Bolin P; Parker K; Kendrick WT; Kendrick SA; Harland RC; Terasaki PI
    Am J Transplant; 2013 Oct; 13(10):2577-89. PubMed ID: 23941128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levels of angiotensin II type-1 receptor antibodies and endothelin-1 type-A receptor antibodies correlate with antibody-mediated rejection and poor graft function in kidney-transplantation patients.
    Liu C; Kang ZY; Yin Z; Xiao Y; Liu W; Zhao Y; Li DH
    Transpl Immunol; 2022 Oct; 74():101674. PubMed ID: 35901953
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Profiling posttransplant circulating antibodies in kidney transplantation using donor endothelial cells.
    Canet E; Devallière J; Gérard N; Karam G; Giral M; Charreau B; Coupel S
    Transplantation; 2012 Feb; 93(3):257-64. PubMed ID: 22234347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pretransplant sensitization against angiotensin II type 1 receptor is a risk factor for acute rejection and graft loss.
    Giral M; Foucher Y; Dufay A; Duong Van Huyen JP; Renaudin K; Moreau A; Philippe A; Hegner B; Dechend R; Heidecke H; Brouard S; Cesbron A; Castagnet S; Devys A; Soulillou JP; Dragun D
    Am J Transplant; 2013 Oct; 13(10):2567-76. PubMed ID: 23919486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical implications of angiotensin II type 1 receptor antibodies in antibody-mediated rejection without detectable donor-specific HLA antibodies after renal transplantation.
    Lee J; Park Y; Kim BS; Lee JG; Kim HJ; Kim YS; Huh KH
    Transplant Proc; 2015 Apr; 47(3):649-52. PubMed ID: 25891704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.